Common Contracts

10 similar Security Agreement contracts by Addex Therapeutics Ltd., Midatech Pharma PLC, Anchiano Therapeutics Ltd., Therapix Biosciences Ltd.

AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD
Security Agreement • April 4th, 2023 • Addex Therapeutics Ltd. • Pharmaceutical preparations

THIS AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 5, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 5, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to 9,230,772 Ordinary Shares, par value CHF 0.01 per share (the “Warrant Shares”), represented by 1,538,462 ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. This Amended and Restated Warrant is issued pursuant to that certain Letter Agreement, dated as of April 3

AutoNDA by SimpleDocs
AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD
Security Agreement • April 4th, 2023 • Addex Therapeutics Ltd. • Pharmaceutical preparations

THIS AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 5, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 5, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to 15,000,000 Ordinary Shares, par value CHF 0.01 per share (the “Warrant Shares”), represented by 2,500,000 ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. This Amended and Restated Warrant is issued pursuant to that certain Letter Agreement, dated as of April

PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD
Security Agreement • April 4th, 2023 • Addex Therapeutics Ltd. • Pharmaceutical preparations

THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 4, 2023 (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to 23,578,950 Ordinary Shares, par value CHF 0.01 per share (the “Warrant Shares”), represented by 3,929,825 ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b)

PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES midatech pharma plc
Security Agreement • February 9th, 2023 • Midatech Pharma PLC • Pharmaceutical preparations

THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _________, 2023 (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by _________ American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). In addition to the other adjustments provided herein, on the sixth (6th) Trading Day following each

PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD
Security Agreement • July 26th, 2022 • Addex Therapeutics Ltd. • Pharmaceutical preparations

THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received,________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _____________ (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to __________________ Ordinary Shares, par value CHF 1.00 per share (the “Warrant Shares”), represented by _________________ ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b)

FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD
Security Agreement • December 20th, 2021 • Addex Therapeutics Ltd. • Pharmaceutical preparations

THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [December ____], 20212 (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Addex Therapeutics Ltd, a Swiss limited company established and existing under the laws of Switzerland (the “Company”), up to ______ Ordinary Shares, par value CHF 1.00 per share (the “Warrant Shares”), represented by ______ ADSs (such ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b)

AMERICAN DEPOSITARY SHARES PURCHASE WARRANT ANCHIANO THERAPEUTICS LTD.
Security Agreement • March 17th, 2021 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations • New York

THIS AMERICAN DEPOSITARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [___], 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [___], 2026 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Anchiano Therapeutics Ltd., an Israeli public company incorporated under the laws of Israel (the “Company”), up to ______ American Depositary Shares (“ADSs”), each ADS representing five (5) ordinary shares, no par value, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AMERICAN DEPOSITARY SHARES PURCHASE WARRANT Therapix Biosciences Ltd.
Security Agreement • July 1st, 2020 • Therapix Biosciences Ltd. • Pharmaceutical preparations • New York

THIS AMERICAN DEPOSITARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January 1, 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 2, 2026 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Therapix Biosciences Ltd., an Israeli public company incorporated under the laws of Israel (the “Company”), up to ______ American Depositary Shares (“ADSs”), each ADS representing forty (40) ordinary shares, NIS 0.10 par value per Ordinary Share, of the Company (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”) (the ADSs issuable hereunder, the “Warrant ADSs”). The purchase price of one ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES midatech pharma plc
Security Agreement • May 20th, 2020 • Midatech Pharma PLC • Pharmaceutical preparations

THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 18, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, d

WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES midatech pharma plc
Security Agreement • October 25th, 2019 • Midatech Pharma PLC • Pharmaceutical preparations

THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the earlier of (x) a time when there is an effective registration statement to cover the issuance of the Warrant ADSs, and such Warrant ADSs or Warrant Shares may be issued free of all legends, each as evidenced by an opinion of counsel reasonably satisfactory to the Depositary delivered to the Depositary, or (y) the entry into a restricted issuance agreement (the “Restricted Issuance Agreement”) by and among the Company , the Depositary and all holders and beneficial owners of restricted American Depositary Shares evidenced by restricted American Depositary Receipts to be issued thereunder, which such Restricted Issuance Agreement shall be in form and substance satisfactory

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!